NR4A1 and prostate adenocarcinoma: Apart from PRAD, 21 additional kinds of tumors also contain the Nur77 mutation, indicating that Nur77 may serve as a prognostic biomarker not only for PRAD patients, but it may also play functions in other kinds of tumors.